Agendia Expands its Business Activities in Germany

The “BRIDGE” initiative offers German patients free access to Agendia’s MammaPrint® breast cancer recurrence assay Data from the MINDACT trial shows MammaPrint is the only test on the German market supported by the highest level of medical evidence (1A) IRVINE, … Continued

New England Journal of Medicine Publishes MINDACT Trial Results Proving the Clinical Utility of MammaPrint® in Assisting Physicians to Identify Early-Stage Breast Cancer Patients who can Safely Forgo Chemotherapy

46% of patients identified as high risk for recurrence according to clinical-pathological factors as described in the publication, and who therefore would be usual candidates for adjuvant chemotherapy, were reclassified as Low Risk by MammaPrint® and MINDACT shows could possibly … Continued

Agendia Appoints Dr. M. William Audeh to Chief Medical Officer

IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, recently announced the appointment of veteran medical oncologist M. William Audeh, MD, MS to the position of Chief Medical Officer. “I’m very pleased … Continued

Agendia Board of Directors Appoints Mark R. Straley as New CEO

IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announced the appointment of veteran diagnostics industry leader Mark R. Straley as Chief Executive Officer.  He succeeds Jan Egberts, M.D, who took … Continued

Agendia Board of Directors Appoints Jan Egberts, M.D., as CEO

Publication Name: Press Release

IRVINE, CA and AMSTERDAM – Agendia, Inc., a leading molecular diagnostic company, today announced the appointment of life science industry veteran and Agendia board member Jan H. Egberts, M.D., as CEO. He replaces David Macdonald, who has left the company … Continued